Press Release: European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease

(marketscreener.com) European Commission approves Enjaymo® for treatment of hemolytic anemia in adult patients with cold agglutinin disease Enjaymo is the first-and-only approved therapeutic option approved for hemolytic anemia in adult patients with cold agglutinin disease Paris, November 17, 2022. The European Commission has granted marketing authorization...https://www.marketscreener.com/quote/stock/SANOFI-4698/news/Press-Release-European-Commission-approves-Enjaymo-sutimlimab-for-treatment-of-hemolytic-anemia-42347048/?utm_medium=RSS&utm_content=20221117